GLPwatch

Structural pharmacology and mechanisms of GLP-1R signaling.

Trends Pharmacol Sci · 2025

Last updated 2026-07-14

GLP-1R is a protein that helps control blood sugar levels. Studies using advanced imaging and analysis methods show how drugs like semaglutide and tirzepatide activate this protein, leading to its effects in treating type 2 diabetes and obesity. These drugs cause changes in the structure of GLP-1R, which then triggers signals inside cells. New research is exploring other ways to influence this protein for potential future treatments.

AI summary of the abstract below.

JournalTrends Pharmacol Sci, 2025
Citations27
Relative citation ratio9.32
Molecules

Abstract

Glucagon-like peptide-1 receptor (GLP-1R), a class B1 G protein-coupled receptor, plays critical roles in glucose homeostasis. Recent structural pharmacology studies using cryogenic electron microscopy, X-ray crystallography, mass spectrometry, and functional analyses, have provided valuable insights into its activation by endogenous hormones and mono- or dual agonists like semaglutide and tirzepatide, highly effective in treating type 2 diabetes and obesity. They highlight significant conformational changes in the extracellular and transmembrane domains of GLP-1R that drive receptor activation and downstream signal transduction. Additionally, allosteric modulators, supported by emerging structural information, show great promises as an alternative strategy. Future research investigating unexplored effector interactions, biased signaling, weight rebound mechanisms, and personalized therapy strategies will be critical for developing better therapeutic agents targeting GLP-1R.

Verbatim abstract via PubMed 40221226 ↗